MRD’s Potential Role in Treating Acute Myeloid Leukemia
0 Vues
• 07/04/23
0
0
Intégrer
administrator
Les abonnés
Harry Erba, MD, PhD; Alexander E. Perl, MD; Eunice Wang, MD; and Jorge E. Cortes, MD, debate the current value of minimal residual disease testing for therapeutic decision-making in acute myeloid leukemia and identify the needs to be addressed before use in standard practice.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires